NeuroOne Medical Technologies CorporationNMTCNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +234.90% | +0.67% | +105.39% | +906.64% | -11.65% |
| Gross Profit Growth | +623.54% | +97.50% | +224.56% | +983.65% | -18.63% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | -175.48% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | -199.77% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | -180.54% |
| EPS Growth | +0.00% | +0.00% | +0.00% | -112.94% | -149.40% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | -112.91% | -149.48% |
| Weighted Average Shares Growth | +28.51% | +20.07% | +77.70% | +50.03% | +63.21% |
| Weighted Average Shares Diluted Growth | +28.69% | +20.07% | +77.70% | +50.03% | +62.99% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | -1597.64% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | -1818.97% |
| Receivables Growth | +335.94% | -42.63% | -100.00% | +616.05% | +12.37% |
| Inventory Growth | +20.03% | +39.87% | +5.81% | -15.50% | -13.71% |
| Asset Growth | +11.54% | -17.39% | +120.24% | +100.85% | +32.08% |
| Book Value per Share Growth | -48.30% | -75.67% | +52.80% | +473.46% | +33.63% |
| Debt Growth | +122.16% | +155.47% | +1.94% | +2.55% | -30.49% |
| R&D Expense Growth | -20.97% | +18.62% | -1.02% | +0.39% | +18.55% |
| SG&A Expenses Growth | -5.98% | -3.12% | -13.94% | -3.39% | -7.73% |